A technological approach for performance status assessment in advanced cancer patients

晚期癌症患者体能状态评估的技术方法

基本信息

  • 批准号:
    10092983
  • 负责人:
  • 金额:
    $ 64.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-01 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Although widely used and accepted in oncology practice to determine patient eligibility and physical tolerance for clinical trial participation, performance status—the single most powerful prognostic and key clinical decision-making tool across all solid tumor types—has one very significant limitation: its subjectivity. Because of the association with survival, performance status scores are routinely assigned by the clinician as a prediction of survival (prognostication). These subjectively determined scores are also used to evaluate fitness capability for treatment, as a stratification and selection factor for clinical trial eligibility, to assess ability to continue treatment on a clinical trial protocol, as a global indicator of quality of life, and to evaluate eligibility and allocation of healthcare funds for hospice and home care services. We propose to examine the association between continuously and objectively measured physical activity (PA) and clinician-assessed performance status scores, overall patient survival, and clinical outcomes of significance (i.e., symptom burden, quality of life measures, death, disease progression, treatment termination due to toxicity, hospitalizations and emergency room visits, and referral for supportive/hospice care). This project will harness the technological capacity of a system (CYCORE) that links home-based monitoring sensors to a cyber-infrastructure and can send data in real time to the patient's healthcare team. To determine if objectively assessed PA levels are associated with health care provider-assessed performance status scores and overall survival, we will recruit 75 patients for each of four performance status groups (levels 0-3). They will provide PA-related data for 7 days by wearing two PA devices—one commercially available and the second research-grade. We will correlate those data with physician-assessed performance status scores and survival outcomes. To evaluate the feasibility of long-term and continuous PA monitoring and the associations with clinical outcomes in advanced cancer patients, we will recruit 100 patients who, for 6 months, will wear a commercially available PA device and will provide PA- and self-reported data from their personal smartphone. We will correlate those data to multiple clinical outcomes. Our long-term goal is to eliminate the subjectivity in performance status assessments.
项目摘要 尽管在肿瘤学实践中广泛使用和接受以确定患者的可用性和身体容忍度 对于临床试验,表现状态 - 最强大的预后和关键临床 所有实体瘤类型的决策工具都是非常重要的局限性:它的主观性。因为 与生存的关联,临床通常将表现状态得分定为一个 预测生存(预后)。这些客观确定的分数也用于评估健身 治疗的能力,作为临床试验资格的分层和选择因子,以评估能力 继续按照临床试验方案进行治疗,作为生活质量的全球指标,并评估资格 以及为临终关怀和家庭护理服务的医疗保健资金分配。我们建议检查关联 在连续和客观测量的体育活动(PA)和临床评估的表现之间 状态评分,整体患者生存和显着性的临床结果(即症状伯恩,质量 生命指标,死亡,疾病进展,由于毒性,住院和治疗终止 急诊室就诊,并转介提供支持/临终关怀)。该项目将利用技术 将基于家庭的监视传感器与网络基础结构联系起来的系统(cycore)的容量 实时发送数据到患者的医疗团队。确定客观评估的PA水平是否为 与由医疗保健提供者评估的绩效状况评分和整体生存有关的相关,我们将招募 四个表现状态组中的每一个患者(0-3级)。他们将为7提供与PA相关的数据 几天,戴着两台PA设备(一种商业上可用)和第二个研究级。我们将 将这些数据与物理评估的性能状态得分和生存结果相关联。评估 长期和连续PA监测的可行性以及与临床结果的关联 晚期癌症患者,我们将招募100名患者,他们将在6个月内穿上商业可用的PA 设备,将从其个人智能手机中提供PA和自我报告的数据。我们将关联这些数据 多个临床结果。我们的长期目标是消除绩效状态的主观性 评估。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael J Overman其他文献

Michael J Overman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael J Overman', 18)}}的其他基金

A technological approach for performance status assessment in advanced cancer patients
晚期癌症患者体能状态评估的技术方法
  • 批准号:
    10356020
  • 财政年份:
    2020
  • 资助金额:
    $ 64.36万
  • 项目类别:
A technological approach for performance status assessment in advanced cancer patients
晚期癌症患者体能状态评估的技术方法
  • 批准号:
    10573160
  • 财政年份:
    2020
  • 资助金额:
    $ 64.36万
  • 项目类别:
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
项目1:高危结直肠癌的个体化辅助免疫治疗。
  • 批准号:
    10415968
  • 财政年份:
    2019
  • 资助金额:
    $ 64.36万
  • 项目类别:
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
项目1:高危结直肠癌的个体化辅助免疫治疗。
  • 批准号:
    10226087
  • 财政年份:
    2019
  • 资助金额:
    $ 64.36万
  • 项目类别:

相似海外基金

Optimizing Advanced Prostate Cancer Care Among US Veterans
优化美国退伍军人的先进前列腺癌护理
  • 批准号:
    10634231
  • 财政年份:
    2023
  • 资助金额:
    $ 64.36万
  • 项目类别:
Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers
晚期癌症患者及其家庭照顾者的心理精神管理
  • 批准号:
    10734689
  • 财政年份:
    2023
  • 资助金额:
    $ 64.36万
  • 项目类别:
Addressing Algorithmic Unreliability and Dataset Shift in EHR-based Risk Prediction Models
解决基于 EHR 的风险预测模型中的算法不可靠性和数据集转移
  • 批准号:
    10679376
  • 财政年份:
    2023
  • 资助金额:
    $ 64.36万
  • 项目类别:
Advancing breast cancer risk prediction in national cohorts: the role of mammogram-based deep learning
推进国家队列中的乳腺癌风险预测:基于乳房 X 光检查的深度学习的作用
  • 批准号:
    10734544
  • 财政年份:
    2023
  • 资助金额:
    $ 64.36万
  • 项目类别:
GARDE: Scalable Clinical Decision Support for Individualized Cancer Risk Management
GARDE:个性化癌症风险管理的可扩展临床决策支持
  • 批准号:
    10741231
  • 财政年份:
    2023
  • 资助金额:
    $ 64.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了